On 29 August 2024, Drug Design, Development and Therapy published the results of a Mabpharm-sponsored phase 1 study regarding CMAB015, biosimilar to Novartis’ Cosentyx® (secukinumab). The study demonstrated that Mabpharm’s CMAB015 showed equivalent pharmacokinetics and comparable safety and immunogenicity to Cosentyx®.
This news follows FDA approval of Celltrion’s global phase 3 trial of its secukinumab biosimilar, CT-P55, in August 2024. Bio-Thera is also developing a biosimilar to Cosentyx®, BAT2306, and commenced a phase 3 clinical trial in November 2022, which is estimated to be completed in the second half of 2024.